Learning Objectives
Upon completion of this activity, participants will be better able to:
- Assess the most recent monotherapy and combination therapy clinical study evidence using available anti-VEGF therapies for common retinal diseases, including AMD.
- Discuss the ocular and systemic effects of anti-VEGF therapies and how to educate patients on appropriate expectations.
- Develop plans to initiate treatment for conditions such as AMD using anti-VEGF agents as well as better understand when to change therapeutic strategies.
Accreditation and Designation Statement
Accreditation and Designation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC,Retina Today and New Retina MD.
Evolve Medical Education LLC designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Off Label Discussion
This educational activity might contain discussion of evidence-based and/or investigational uses of agents that are not indicated by the FDA. For additional information about approved uses, please refer to the official prescribing information.
Faculty and Disclosures
- SriniVas Sadda, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Carl Zeiss Meditec and Optos. Grant/Research Support: Carl Zeiss Meditec and Optos.
- Richard F. Spaide, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Topcon Corporation.
- Rishi P. Singh, MD, Peer Reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan Plc; Carl Zeiss Meditec; Genentech, Inc; Optos; Regeneron Pharmaceuticals, Inc; and Shire Plc. Grant/Research Support: Alcon; Apellis Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.
- Cheryl Cavanaugh, MS, Evolve Medical Education LLC; and Michelle Dalton, Writer, have no relevant commercial interests to disclose.
Video Resources
AMD 2017: Managing Patient Expectations for Anti-VEGF Therapies
By: SriniVas Sadda, MD; Richard F. Spaide, MD; Rishi P. Singh, MD; Cheryl Cavanaugh, MS; and Michelle Dalton
BackNext
